Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Capital Employed (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Return on Capital Employed for 10 consecutive years, with 0.57% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 7.0% to 0.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.57% through Dec 2025, down 7.0% year-over-year, with the annual reading at 0.48% for FY2025, 1.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.57% at Intellia Therapeutics, up from 0.58% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.23% in Q4 2021, with the low at 0.6% in Q2 2025.
  • Average Return on Capital Employed over 5 years is 0.41%, with a median of 0.42% recorded in 2023.
  • The sharpest move saw Return on Capital Employed grew 16bps in 2021, then decreased -19bps in 2022.
  • Over 5 years, Return on Capital Employed stood at 0.23% in 2021, then tumbled by -73bps to 0.39% in 2022, then fell by -14bps to 0.45% in 2023, then decreased by -12bps to 0.5% in 2024, then fell by -13bps to 0.57% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.57%, 0.58%, and 0.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.